StudyRareStudyRare

Second-trimester soft markers

Log in to star

Last updated Nov 9, 2026

Log in to add personal notes on this page.

A soft marker is a minor finding on the second-trimester anatomy scan that is usually not a structural abnormality, is often a normal variant, and matters because it raises the probability of aneuploidy, mostly trisomy 21. A major anomaly (a heart defect, spina bifida) affects health on its own; a soft marker usually does not.

Isolated has a precise meaning (SMFM Consult #57, 2021): no structural anomaly, no growth restriction, and no second soft marker on a detailed anatomy scan. One marker is the indication for that scan. Two markers, or a marker plus a structural anomaly, get an individualized workup.

  1. Is it really isolated? Detailed scan first.
  2. What did prior screening show? A negative cell-free DNA (cfDNA) result lowers the risk of trisomy 21 about 300-fold: a 35-year-old at 1 in 356 falls below 1 in 50,000. Serum screens detect 81% to 99% of trisomy 21 and leave more residual risk.
  3. What else can it mean? Cystic fibrosis, cytomegalovirus (CMV), growth restriction, skeletal dysplasia, urinary tract disease. That follow-up continues whatever the aneuploidy result.

Using a likelihood ratio

Multiply the prior risk by the LR. A 1 in 1,000 age-related risk with a thickened nuchal fold (LR 23.3) becomes 23.3 in 1,000, about 1 in 43.

The trap is which LR. The unadjusted positive LR comes from fetuses that often had other findings. The isolated-marker LR multiplies it by the negative LRs of every marker that was absent, and it is far smaller: 3.79 for nuchal fold, which turns the same 1 in 1,000 into about 1 in 264. An echogenic focus drops from 5.8 to 0.95.

Isolated LRs: Agathokleous et al. (2013), via Gardner and Amor Table 20-5. Choroid plexus cyst and single umbilical artery rows: SMFM #57.

MarkerDefinitionIsolated LR for trisomy 21After a low-risk screen
Thickened nuchal fold6 mm or more at 15 to 20 weeks3.79After serum screening: counsel. After cfDNA: nothing
Absent or hypoplastic nasal boneAbsent, or short for gestational age6.58Same as nuchal fold
Echogenic intracardiac focusUnder 6 mm, as bright as bone, in 2 planes0.95Nothing
Echogenic bowelAs bright as the iliac bone or brighter1.65Cystic fibrosis and CMV evaluation; growth scan
Choroid plexus cystEcholucent cyst in the choroid, usually under 1 cmNone (trisomy 18 LR under 2)Nothing
Mild ventriculomegalyAtrium 10 to 12 mm3.81Outside SMFM #57
Urinary tract dilation A1Renal pelvis 4 to under 7 mm before 28 weeks, 7 to under 10 mm after1.08Scan at 32 weeks
Short femurObserved to expected length under 0.920.78Growth scan
Short humerusObserved to expected length under 0.900.61Growth scan
Single umbilical arteryOne artery and one veinNo increaseGrowth scan; weekly testing from 36 weeks

Thickened nuchal fold. One of the most specific markers (unadjusted LR 11 to 23). Not the first-trimester nuchal translucency.

Absent or hypoplastic nasal bone. In 0.1% to 1.2% of euploid fetuses and 9% of Afro-Caribbean fetuses. Other genetic syndromes cause it too, so review the anatomy.

Echogenic intracardiac focus. Papillary muscle mineralization, not a heart defect. In 3% to 5% of euploid fetuses, more in Middle Eastern and Asian populations.

Echogenic bowel. Aneuploidy in 3% to 5%. Also cystic fibrosis (0% to 13%), CMV (2% to 4%), swallowed blood after bleeding or a procedure, growth restriction, and bowel obstruction.

Choroid plexus cyst. In 1% to 2% of fetuses and 30% to 50% of fetuses with trisomy 18, who nearly always show other anomalies (LR 66 with a structural anomaly). Size, side, and persistence do not change the risk; nearly all resolve by 28 weeks.

Mild ventriculomegaly. Also neural tube defects, CMV, and toxoplasmosis; fetal MRI can help.

Urinary tract dilation. The current name for pyelectasis. A2-3 means a larger pelvis, peripheral calyceal dilation, abnormal parenchyma, ureters, or bladder, or unexplained oligohydramnios.

Short femur and humerus. Measured against the biparietal diameter, not dates. Also skeletal dysplasia, constitutionally short bones, and growth restriction.

Single umbilical artery. With other anomalies, aneuploidy runs 4% to 50%. Isolated, the concern is stillbirth and possibly growth restriction.

Minor findings. Sandal gap and fifth-finger clinodactyly are associated with trisomy 21; SMFM #57 does not address them.

SMFM Consult #57 (2021):

  1. After a negative serum or cfDNA screen, no diagnostic testing solely for an isolated marker. A patient may still choose it.
  2. No prior screening: counsel on the trisomy 21 risk (trisomy 18 for a choroid plexus cyst) and offer cfDNA (quad screen if cfDNA is unavailable).
  3. Nuchal fold or nasal bone: with no prior screening, amniocentesis is also an option. After a negative serum screen: no further testing, cfDNA, or amniocentesis. After a negative cfDNA, nothing further.
  4. Echogenic focus and choroid plexus cyst: normal variants. No follow-up scan or newborn evaluation, and no fetal echocardiogram for the focus.
  5. Echogenic bowel: parental CFTR carrier testing, CMV IgG and IgM (see TORCH infections), and a third-trimester growth scan.
  6. Urinary tract dilation A1: scan at 32 weeks to decide on newborn urology or nephrology follow-up. A2-3: individualized scans and planned newborn follow-up.
  7. Short long bones: third-trimester growth scan.
  8. Single umbilical artery: no aneuploidy evaluation even without prior screening; third-trimester growth scan; consider weekly fetal testing from 36 0/7 weeks.
  • A choroid plexus cyst is a trisomy 18 marker; it does not change the trisomy 21 risk.
  • Nuchal fold and nasal bone are the only markers that keep amniocentesis on the table after a negative serum screen.
  • A single umbilical artery is the only marker where screening status does not matter.
  • After a negative cfDNA result, even an isolated absent nasal bone leaves the risk very low: 1 in 50,000 times 6.58 is about 1 in 7,600.
  • For patients who declined screening, SMFM asks each practice to set a protocol for isolated markers and explain it before the scan.
  • Tell the pediatric team at delivery about echogenic bowel, urinary tract dilation, and a single umbilical artery.